Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation
机构:[1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China,[2]Department of Rheumatology and Immunology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China,大德路总院风湿科风湿免疫研究团队广东省中医院[3]HKBU Shenzhen Research Center, Shenzhen, China,[4]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong,[5]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China
Rheumatoid arthritis is a chronic inflammatory autoimmune disease, causing articular and extra-articular dysfunctions among patients, and it could result in irreversible joint damages or disability if untreated. A traditional Chinese medicine formula, Huayu-Qiangshen-Tongbi (HT) formula, has been observed successful in controlling rheumatoid arthritis progression in traditional Chinese medicine clinics. In this study, we conducted a systematic analysis of the HT formula with a purpose of proposing for its potential mechanism of action using network pharmacological methods. The potential targets of the formula were collected and screened according to the topological features of their protein-protein interaction network, and we subsequently validated our prediction results through in vitro experiments. We proposed that the HT formula could interfere with the bone metabolism and the inflammatory pathways of the body. The experimental validation results indicated that HT formula could exhibit anti-inflammatory effects by regulating several signaling pathways specifically the Toll-like receptor signaling pathway, phosphoinositide-3-kinase-Akt signaling pathway, hypoxia-inducible factor 1 signaling pathway, mitogen-activated protein kinase signaling pathway and activator protein 1 signaling pathway.
基金:
National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China [81470170]; Macau Science and Technology Development Fund [013/2015/A1]; University of Macau [MYRG2016-00144-ICMS-QRCM, MYRG2017-00178-ICMS, MYRG2018-00043-ICMS]; Guangdong-Macao Traditional Chinese Medicine Technology Industrial Park [D-Pro-0274-2017]; Natural Science Foundation of ChinaNational Natural Science Foundation of China [81774218]; Guangdong Provincial Hospital of Chinese Medicine [YN2018ML08, YN2018ZD06]; Science and Technology Project of Guangdong Province [2016A020226041]; 1010 Project of Guangdong Provincial Hospital of Chinese Medicine [YN10101906]; Guangzhou Municipal Science and Technology Innovation Committee [201710010076]; Science and Technology Planning Project of Guangdong Province [2017B030314166]
第一作者机构:[1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China,
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China,[3]HKBU Shenzhen Research Center, Shenzhen, China,[4]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong,
推荐引用方式(GB/T 7714):
Wang Zihao,Linghu Ke-Gang,Hu Yuanjia,et al.Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation[J].FRONTIERS IN PHARMACOLOGY.2019,10:doi:10.3389/fphar.2019.01065.
APA:
Wang, Zihao,Linghu, Ke-Gang,Hu, Yuanjia,Zuo, Huali,Yi, Hao...&Huang, Run-Yue.(2019).Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation.FRONTIERS IN PHARMACOLOGY,10,
MLA:
Wang, Zihao,et al."Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation".FRONTIERS IN PHARMACOLOGY 10.(2019)